

IPR2024-00107
U.S. Patent 10,335,462

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SUN PHARMACEUTICAL INDUSTRIES LTD.
and
SUN PHARMACEUTICAL INDUSTRIES, INC.,

Petitioners

v.

NOVO NORDISK A/S,
Patent Owner

Case IPR2024-00107
Patent 10,335,462

PRELIMINARY RESPONSE
UNDER 37 C.F.R. §42.107

LIST OF EXHIBITS

Exhibit	Description
EX2001	Excerpt of Defendants' Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC (D. Del. Oct. 20, 2022)
EX2002	Petition for <i>Inter Partes</i> Review, <i>Mylan Pharms. Inc. v. Novo Nordisk A/S</i> , IPR2023-00724, Pap.1 (Mar. 16, 2023)
EX2003	Declaration of Sayem Osman
EX2004	Stipulation and Order Regarding Trial of the MPI Ozempic Litigation, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC, Dkt. 245 (D. Del. Oct. 31, 2023)
EX2005	Nov. 29, 2023 Email from E. Goldschlager to Counsel, re: IPR2023-00724 – Request for Conference Call
EX2006	Scheduling Order, <i>Novo Nordisk Inc. v. Rio Biopharms., Inc.</i> , No. 1:22-cv-00294-CFC, Dkt. 22 (D. Del. June 30, 2022)
EX2007	Excerpt of Transcript of Dec. 13, 2023 Claim Construction Hearing, <i>Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc.</i> , No. 23-101-CFC (D. Del. Dec. 13, 2023)
EX2008	Claim Construction Order, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC, Dkt. 148 (D. Del. July 25, 2023)
EX2009	Joint Stipulation and Order Amending Scheduling Order, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , MDL No. 22-MD-03038-CFC, Dkt. 268 (D. Del. Dec. 1, 2023)
EX2010	Excerpt of Novo Nordisk's Third Amended Disclosures to Defendants Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc., <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC (D. Del. July 28, 2023)
EX2011	U.S. Patent No. 8,114,833
EX2012	Summons in a Civil Action, Sun Pharmaceutical Industries, Inc., <i>Novo Nordisk Inc. v. Sun Pharmaceutical Indus. Ltd.</i> , No. 1:22-cv-00296-CFC, Dkt. 7 (D. Del. Mar. 7, 2022)
EX2013	Summons in a Civil Action, Sun Pharmaceutical Industries Ltd., <i>Novo Nordisk Inc. v. Sun Pharmaceutical Indus. Ltd.</i> , No. 1:22-cv-00296-CFC, Dkt. 8 (D. Del. Mar. 16, 2022)

Exhibit	Description
EX2014	Excerpt of Redacted Patent Owner's Response, <i>Mylan Pharms. Inc. v. Novo Nordisk A/S</i> , IPR2023-00724, Pap.30 (Jan. 17, 2023)
EX2015	Excerpt of Novo Nordisk's Initial Responses to Defendants' Initial Invalidation Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC (D. Del. Dec. 21, 2022) [REDACTED]
EX2016	Transfer Order, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC, Dkt. 1 (D. Del. Aug. 5, 2022)
EX2017	INTENTIONALLY OMITTED
EX2018	Excerpt of Defendants' Second Supplemental Invalidation Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC (D. Del. Jan. 12, 2024) [REDACTED]
EX2019	Novo Nordisk Production Letter, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC (D. Del. Oct. 17, 2023) [REDACTED]
EX2020	Compilation of Defendants' Production Letters, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC (D. Del.) [REDACTED]
EX2021	Compilation of Rule 30(b)(1) Deposition Notices, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC (D. Del.)
EX2022	Notice of Service for Defendants' Initial Invalidation Contentions, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC (D. Del. Oct. 20, 2022)
EX2023	Notice of Service for Defendants' Supplemental Invalidation Contentions, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC (D. Del. Nov. 6, 2023)
EX2024	Stipulation for Extension of Time, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC, Dkt. 309 (D. Del. Feb. 9, 2024)
EX2025	February 26, 2024 Email from C. Ferenc to M. Raymond, re: IPR2024-00107

Exhibit	Description
EX2026	Sun Pharmaceutical Industries Ltd.'s and Sun Pharmaceutical Industries Inc.'s Stipulation of Invalidity Contentions, <i>Novo Nordisk Inc. v. Rio Biopharmaceuticals Inc.</i> , No. 22-cv-00294-CFC, Dkt. 275 (D. Del. Nov. 6, 2023)
EX2027	Joint Stipulation and Order Extending Deadline for Certain Fact Discovery, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 22-MD-03038-CFC, Dkt. 305 (D. Del. Feb. 6, 2024)

TABLE OF CONTENTS

I. Introduction.....1

II. *Fintiv* Is Appropriate and Necessary to Consider Before Institution4

III. This is PO’s First Genuine Opportunity to Brief *Fintiv* in Connection with
Petitioner’s Delaware Litigation.....5

IV. Institution Should Be Denied Under 35 U.S.C. §314(a).....7

 A. The Parallel Litigation Will Not Be Stayed (Factor 1).....7

 B. Even if Mylan’s Final Written Decision Date Were Considered, the
 Parallel Litigation Trial Date Precedes It; and No Final Written
 Decision Date Will Apply if This Petition is Instituted and Joinder is
 Granted (Factor 2).....9

 C. The Court and Parties Have Already Invested Significantly in the
 Parallel Litigation (Factor 3).....13

 D. There Is Overlap Between Issues Raised in the Petition and in the
 Parallel Litigation (Factor 4).....17

 E. Petitioner Is a Defendant in the Parallel Litigation (Factor 5)23

 F. Other Circumstances that Impact the Board’s Exercise of Discretion,
 Including the Merits (Factor 6).....24

V. Conclusion25

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.